15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 20 firms covering Revolution Medicines Inc, 19 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $72.00 to $236.00 (about 3.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $175.22 sits 5% below the current $183.95. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.99 next quarter toward $-5.80 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS20 ratings
Moderate Buy
Strong Buy15%
Buy1890%
Hold15%
Sell00%
Strong Sell00%
Based on 20 analysts giving stock ratings to Revolution Medicines Inc.
As of Jul, 19 of 20 firms rate RVMD a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
RVMD EPS & revenue forecast
EPS · NEXT QUARTER
$-1.99
Range $-2.14 – $-1.87 · 16 analysts · +24% YoY
Next period, 16 analysts expect Revolution Medicines Inc to earn $-1.99 a share (range $-2.14 – $-1.87), versus $-1.61 a year earlier. Full-year consensus is $-8.07, growing to $-5.80 the year after.
REVENUE · NEXT QUARTER
$7.4M
Range $0 – $37.3M · 16 analysts
Revenue is expected to reach $7.4M (range $0 – $37.3M). Full-year consensus is $103.3M, rising to $881.2M next year.
Top analysts covering Revolution Medicines Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RVMD.
#1
Michael Schmidt
Guggenheim · Rank #1
Buy
$235.00+27.8% to target
Overall win rate
55%
+ Follow
#2
Leonid Timashev
RBC Capital · Rank #69
Buy
$182.00-1.1% to target
Overall win rate
42%
+ Follow
#3
Ami Fadia
Needham · Rank #90
Buy
$236.00+28.3% to target
Overall win rate
46%
+ Follow
#4
RB
Robert Burns
HC Wainwright & Co. · Rank #195
Buy
$195.00+6.0% to target
Overall win rate
38%
+ Follow
#5
Jay Olson
Oppenheimer · Rank #302
Buy
$195.00+6.0% to target
Overall win rate
32%
+ Follow
RVMD stock forecast FAQ
What is RVMD's average 12-month price target?+
The 18 analysts with a live target average $175.22 for Revolution Medicines Inc over the next 12 months, ranging from a $236.00 high to a $72.00 low.
Is RVMD stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 20 analyst ratings, 19 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for RVMD?+
The Street-high target is $236.00 (Needham), and the Street-low is $72.00 (Raymond James). The average of all 18 active targets is $175.22.
How many Wall Street analysts cover RVMD?+
20 analysts have an active rating on Revolution Medicines Inc, and 18 firms carry a live 12-month price target.
Who is the most accurate analyst covering RVMD?+
Among analysts who currently cover RVMD, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #1). Their current call is Buy with a $235.00 target.
What is Revolution Medicines Inc's projected EPS for next quarter?+
The consensus estimate is $-1.99 per share (range $-2.14 – $-1.87) across 16 analysts. Full-year EPS is projected at $-8.07, rising to $-5.80 the following year.
How much revenue is Revolution Medicines Inc expected to report next quarter?+
Consensus revenue is $7.4M (range $0 – $37.3M). Full-year revenue is projected at $103.3M, growing to $881.2M next year.
Have analysts been upgrading or downgrading RVMD lately?+
As of Jul, 19 of 20 firms rate RVMD a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RVMD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
